Oculis (NASDAQ:OCS) Shares Gap Down – Should You Sell?

Posted by Brian Himes on Sep 18th, 2026

Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $10.60, but opened at $10.11. Oculis shares last traded at $9.8590, with a volume of 5,224 shares traded.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OCS. JPMorgan Chase & Co. decreased their price target on Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, August 14th. HC Wainwright reissued a “buy” rating on shares of Oculis in a research report on Tuesday, August 25th. Needham & Company LLC reduced their price target on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Guggenheim decreased their price target on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a report on Monday, June 1st. Finally, Wall Street Zen upgraded shares of Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Oculis has an average rating of “Moderate Buy” and a consensus target price of $38.00.

View Our Latest Stock Analysis on OCS

Oculis Price Performance

The company has a market capitalization of $578.64 million, a price-to-earnings ratio of -5.74 and a beta of 0.52. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01. The company’s 50 day simple moving average is $12.10 and its 200-day simple moving average is $19.01.

Oculis (NASDAQ:OCS – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. On average, equities research analysts predict that Oculis Holding AG will post -2.01 earnings per share for the current fiscal year.

Institutional Trading of Oculis

Several institutional investors have recently made changes to their positions in the stock. Koshinski Asset Management Inc. purchased a new stake in Oculis during the first quarter valued at about $238,000. Himension Capital Singapore PTE. LTD. purchased a new stake in shares of Oculis during the first quarter valued at approximately $503,000. Y Intercept Hong Kong Ltd purchased a new stake in Oculis during the 1st quarter worth $776,000. Squarepoint Ops LLC boosted its position in Oculis by 326.4% in the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock valued at $854,000 after buying an additional 47,158 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Oculis by 9.1% during the first quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after acquiring an additional 5,813 shares in the last quarter. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Company Profile

(Get Free Report)

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis’ pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.